中國Court CasesCourtsEIP Coffee BreakEIP Patent 101 CornerprosecutionSupreme People's Court
2021年8月19日

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape

Seminal Cases by the SPC

Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for similar cases in the future, so they are still worthy of attention.

One of the seminal cases ((2020) 最高法知民终699号) is very interesting. It involves a set of “same day applications”, i.e. an invention patent and utility model (UM) patent directed towards the same invention filed on the same day. The key issue is: if the invention patent application is rejected, what happens to the corresponding granted UM?

A Bit of Background

China allows patent applicants to apply for Invention and UM patents for the same invention on the same day (same-day applications). Typically the UM grants first (within 5-8 months), allowing the patentee to initiate license agreements or enforcement actions based thereon. Then later, when (and if) the time-consuming and costly invention application finally proceeds to grant, the applicant can obtain an invention patent’s longer 20-year protection term by giving up the UM patent (10 year term). Applicants welcome this dual application strategy, since it provides fast and comprehensive protection for product inventions.

Same Day Applications

In this seminal case, the applicant had obtained a granted UM earlier, but the corresponding invention patent application had been finally rejected, even after a re-examination request and administrative suit. Later the patentee initiated an infringement lawsuit based on the same-day UM patent which protects an identical technical solution. The first instance held in favor of the patentee. The SPC revoked the judgment of the first instance and held that in this case, the patent right for the utility model should be questioned.

Generally speaking, if a same-day invention application is rejected for lacking novelty, then the related same-day UM patent must also lack novelty, and thus will not meet the grant requirements. However, if the invention application is rejected for lack of inventiveness, then the judge cannot directly arrive at the same conclusion, since inventiveness requirements for invention patents and UMs are different.

We believe that this judgment is reasonable and will effectively reduce litigation costs in similar situations. We are of view that this judgment will not have significant impact on the same-day filing strategy for high-quality inventions.

You may refer to our previous article regarding same-day filing strategy.

(http://ipc.court.gov.cn/m/detail.html?id=1410)

About the Authors

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

How to Protect a Crystal Form (Polymorph) Patent in China

2025年6月4日
Crystalline forms are critical to pharmaceutical patents, offering extended protection for improved stability, bioavailability, or manufacturability. However, securing such patents in China has grown increasingly difficult due to the China National Intellectual Property Administration (CNIPA)’s strict patentability criteria. Unlike the U.S. or Europe, where structural novelty or problem-solving utility may suffice, China demands quantifiable evidence of […]

CHINA: New Patent Examination Guidelines Now Available for Public Comment

2021年8月4日
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]

我們過去活動

Top crossarrow-right